Interferon Alfa-2A: Clinical Trials

20 trials of Interferon Alfa-2A, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 1 terminated, 1 unknown, 1 withdrawn. 10 Phase 2, 6 Phase 1, 3 Phase 3, 1 Not applicable, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 210Completed 8, Terminated 1, Withdrawn 1
Phase 16Completed 5, Withdrawn 1
Phase 33Completed 3
Not applicable1Unknown 1
Phase 41Completed 1

Follow Interferon Alfa-2A: new trials by email Literature Review of Interferon Alfa-2A trials Research Report on Interferon Alfa-2A

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.
Nucleotide Analog, Interferon Alfa-2A - Hepatitis B
Not applicableUnknownSun Yat-sen University4002018-12-012023-05-08
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis
Phase 3CompletedPeking Union Medical College Hospital282017-06-302021-02-23
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
TG-2349, Ribavirin, Interferon Alfa-2a - Hepatitis C, Chronic
Phase 2CompletedTaiGen Biotechnology Co., Ltd.252015-05-012023-07-14
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A) - Chronic Lymphocytic Leukemia
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2011-04-012012-08-03
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
bevacizumab [Avastin], interferon alfa-2a - Renal Cell Cancer
Phase 2CompletedHoffmann-La Roche1462008-12-012015-05-27
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
RAD001(everolimus), interferon alfa-2a, bevacizumab - Carcinoma, Adenocarcinoma
Phase 2CompletedNovartis Pharmaceuticals3652008-11-122017-03-20
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
bevacizumab [Avastin], Interferon alfa-2a, Vinblastine - Renal Cell Cancer
Phase 2CompletedHoffmann-La Roche252007-09-012014-10-13
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
Pioglitazone, Interferon Alfa-2a, Ribavirin - Chronic Hepatitis C
Phase 2CompletedUniversity Hospital, Geneva52007-01-012015-05-28
Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines
Interferon Alfa-2a - Cancer
Phase 2TerminatedDuke University112005-11-012014-07-25
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
Peginterferon alfa-2a, Interferon alfa-2a - Chronic Hepatitis C, End Stage Renal Disease
Phase 4CompletedNational Taiwan University Hospital502005-07-012008-03-06
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin - Hepatitis C
Phase 3CompletedFoundation for Liver Research332003-02-012021-09-01
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a - HIV Infections, Hepatitis C
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1322000-11-012021-11-01
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Interferon Alfa-2a, Interleukin-2 - Carcinoma, Renal Cell
Phase 3CompletedGruppo Oncologico Italiano di Ricerca Clinica3101994-07-012013-07-10
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
Interferon alfa-2a, Zidovudine, Interferon alfa-n1 - Sarcoma, Kaposi, HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)482021-11-04
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
Isotretinoin, Interferon alfa-2a - HIV Infections, Anus Neoplasms
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)982021-10-28
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
Interferon alfa-2a, Zidovudine, Zalcitabine - HIV Infections
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)602021-11-04
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
Interferon alfa-2a, Zidovudine - Sarcoma, Kaposi, HIV Infections
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)602021-11-03
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
Interferon alfa-2a, Zidovudine - HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)482021-11-02
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
Interferon alfa-2a, Zidovudine, Interferon alfa-n1 - Sarcoma, Kaposi, HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)562021-11-03
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
Interferon alfa-2a, Zidovudine - HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)522021-10-29

Conditions studied

HIV Infections (8)  ·  Acquired Immunodeficiency Syndrome (5)  ·  AIDS-Related Complex (4)  ·  Carcinoma, Renal Cell (4)  ·  Hepatitis C, Chronic (4)  ·  Sarcoma, Kaposi (3)  ·  Hepatitis C (2)  ·  Adenocarcinoma (1)  ·  Anus Neoplasms (1)  ·  Behcet Syndrome (1)  ·  Carcinoma (1)  ·  Hepatitis B (1)  ·  Hepatitis B, Chronic (1)  ·  Influenza, Human (1)  ·  Insulin Resistance (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (8)  ·  Hoffmann-La Roche (2)  ·  Duke University (1)  ·  Foundation for Liver Research (1)  ·  Gruppo Oncologico Italiano di Ricerca Clinica (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Taiwan University Hospital (1)  ·  Novartis Pharmaceuticals (1)  ·  Peking Union Medical College Hospital (1)  ·  Sun Yat-sen University (1)  ·  TaiGen Biotechnology Co., Ltd. (1)  ·  University Hospital, Geneva (1)

Countries

United States (9)  ·  Germany (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Switzerland (3)  ·  Taiwan (3)  ·  China (2)  ·  Czechia (2)  ·  Russia (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Egypt (1)  ·  Estonia (1)  ·  Finland (1)

Top investigators

Fischl MA (2)  ·  Amar Safdar, MD (1)  ·  Carlo Buzio, Medicine (1)  ·  Chan Xie (1)  ·  Chen-Hua Liu, M.D. (1)  ·  Critchlow C (1)  ·  D Mildvan (1)  ·  Diaz C (1)  ·  Francesco Negro, Prof (1)  ·  Kaplan LD (1)  ·  Krown S (1)  ·  M Fischl (1)  ·  Michael Morse, MD (1)  ·  Ming-Lung Yu (1)

Results publications

PMID 15282352, PMID 15563253, PMID 15685543, PMID 15867490, PMID 16115185, PMID 16439867, PMID 20622678, PMID 23803225, PMID 25304727, PMID 25851632, PMID 37096802, PMID 37146227, PMID 38923559

NIH funding

2008 (1)